Highlights & Basics
- Renal tubular acidosis (RTA) is a clinical syndrome characterized by hyperchloremic metabolic acidosis with a normal serum anion gap.
- Adult patients with RTA are often asymptomatic but may present with muscular weakness related to associated hypokalemia, nephrocalcinosis, or recurrent renal stones.
- There are four types of RTA: classic distal RTA (type I), proximal RTA (type II), hyperkalemic distal RTA (type IV), and a rare combination of proximal and distal RTA caused by carbonic anhydrase II deficiency and carbonic anhydrase inhibitors blocking the metabolism of bicarbonate and carbonic acid (type III).
- Alkali therapy is the mainstay of treatment in all forms of RTA.
- If hyperkalemic distal RTA is due to mineralocorticoid deficiency, fludrocortisone can be given unless it is contraindicated due to the presence of fluid overload or uncontrolled hypertension.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
Palmer BF, Kelepouris E, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. Adv Ther. 2021 Feb;38(2):949-68.[Abstract][Full Text]
Kashoor I, Batlle D. Proximal renal tubular acidosis with and without Fanconi syndrome. Kidney Res Clin Pract. 2019 Sep 30;38(3):267-81.[Abstract][Full Text]
Giglio S, Montini G, Trepiccione F, et al. Distal renal tubular acidosis: a systematic approach from diagnosis to treatment. J Nephrol. 2021 Mar 26 [online ahead of print].[Abstract][Full Text]
Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002 Aug;13(8):2160-70.[Abstract][Full Text]
Batlle D, Arruda J. Hyperkalemic forms of renal tubular acidosis: clinical and pathophysiological aspects. Adv Chronic Kidney Dis. 2018 Jul;25(4):321-33.[Abstract]
Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis: core curriculum 2016. Am J Kidney Dis. 2016 Sep;68(3):488-98.[Abstract][Full Text]
1. Palmer BF, Kelepouris E, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. Adv Ther. 2021 Feb;38(2):949-68.[Abstract][Full Text]
2. Kashoor I, Batlle D. Proximal renal tubular acidosis with and without Fanconi syndrome. Kidney Res Clin Pract. 2019 Sep 30;38(3):267-81.[Abstract][Full Text]
3. Giglio S, Montini G, Trepiccione F, et al. Distal renal tubular acidosis: a systematic approach from diagnosis to treatment. J Nephrol. 2021 Mar 26 [online ahead of print].[Abstract][Full Text]
4. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol. 2002 Aug;13(8):2160-70.[Abstract][Full Text]
5. Alexander RT, Law L, Gil-Peña H, et al. Hereditary distal renal tubular acidosis. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews. Seattle (WA): University of Washington, Seattle; Oct 2019 [internet publication].[Abstract][Full Text]
6. Fuster DG, Moe OW. Incomplete distal renal tubular acidosis and kidney stones. Adv Chronic Kidney Dis. 2018 Jul;25(4):366-74.[Abstract]
7. Foreman JW. Fanconi syndrome. Pediatr Clin North Am. 2019 Feb;66(1):159-67.[Abstract]
8. Besouw MTP, Bienias M, Walsh P, et al. Clinical and molecular aspects of distal renal tubular acidosis in children. Pediatr Nephrol. 2017 Jun;32(6):987-96.[Abstract]
9. Tatu CA, Orem WH, Finkelman RB, et al. The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect. 1998 Nov;106(11):689-700.[Abstract][Full Text]
10. Stefanovic V, Plenakovic M. Fifty years of research in Balkan endemic nephropathy: where are we now? Nephron Clin Pract. 2009;112(2):c51-6.[Abstract][Full Text]
11. Nimmannit S, Malasit P, Susaengrat W, et al. Prevalence of endemic distal renal tubular acidosis and renal stone in the northeast of Thailand. Nephron. 1996;72(4):604-10.[Abstract]
12. Pun KK, Wong CK, Tsui EY, et al. Hypokalemic periodic paralysis due to the Sjögren syndrome in Chinese patients. Ann Intern Med. 1989 Mar 1;110(5):405-6.[Abstract]
13. Bianic F, Guelfucci F, Robin L, et al. Epidemiology of distal renal tubular acidosis: a study using linked UK primary care and hospital data. Nephron. 2021;145(5):486-95.[Abstract]
14. Mohebbi N, Wagner CA. Pathophysiology, diagnosis and treatment of inherited distal renal tubular acidosis. J Nephrol. 2018 Aug;31(4):511-22.[Abstract]
15. Karet FE. Inherited distal renal tubular acidosis. J Am Soc Nephrol. 2002 Aug;13(8):2178-84.[Abstract][Full Text]
16. Elmonem MA, Veys KR, Soliman NA, et al. Cystinosis: a review. Orphanet J Rare Dis. 2016 Apr 22;11:47.[Abstract][Full Text]
17. Senemar S, Ganjekarimi A, Senemar S, et al. The prevalence and clinical study of galactosemia disease in a pilot screening program of neonates, southern iran. Iran J Public Health. 2011 Dec;40(4):99-104.[Abstract][Full Text]
18. Palmer BF, Clegg DJ. Hyperchloremic normal gap metabolic acidosis. Minerva Endocrinol. 2019 Dec;44(4):363-77.[Abstract]
19. Batlle D, Arruda J. Hyperkalemic forms of renal tubular acidosis: clinical and pathophysiological aspects. Adv Chronic Kidney Dis. 2018 Jul;25(4):321-33.[Abstract]
20. Bello CHPRT, Duarte JS, Vasconcelos C. Diabetes mellitus and hyperkalemic renal tubular acidosis: case reports and literature review. J Bras Nefrol. 2017 Oct-Dec;39(4):481-5.[Abstract][Full Text]
21. Schwarz C, Benesch T, Kodras K, et al. Complete renal tubular acidosis late after kidney transplantation. Nephrol Dial Transplant. 2006 Sep;21(9):2615-20.[Abstract][Full Text]
22. Kocyigit I, Unal A, Kavuncuoglu F, et al. Renal tubular acidosis in renal transplantation recipients. Ren Fail. 2010 Jul;32(6):687-90.[Abstract]
23. Online Mendelian Inheritance in Man (OMIM). Fanconi renotubular syndrome 1; FRTS 1: gene map locus 15q15.3. May 2017 [internet publication].[Full Text]
24. Patil S, Subramany S, Patil S, et al. Ibuprofen abuse-a case of rhabdomyolysis, hypokalemia, and hypophosphatemia with drug-induced mixed renal tubular acidosis. Kidney Int Rep. 2018 Jun 8;3(5):1237-8.[Abstract][Full Text]
25. Ng JL, Morgan DJR, Loh NK, et al. Life-threatening hypokalemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust. 2011 Mar 21;194(6):313-6.[Abstract]
26. Medland NA, Chow EP, Walker RG, et al. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate. Int J STD AIDS. 2018 Mar;29(3):227-36.[Abstract]
27. Palazzo V, Provenzano A, Becherucci F, et al. The genetic and clinical spectrum of a large cohort of patients with distal renal tubular acidosis. Kidney Int. 2017 May;91(5):1243-55.[Abstract]
28. Watanabe T. Improving outcomes for patients with distal renal tubular acidosis: recent advances and challenges ahead. Pediatric Health Med Ther. 2018 Dec 12;9:181-90.[Abstract][Full Text]
29. Alexander RT, Bitzan M. Renal tubular acidosis. Pediatr Clin North Am. 2019 Feb;66(1):135-57.[Abstract]
30. El Bitar S, Weerasinghe C, El-Charabaty E, et al. Renal tubular acidosis an adverse effect of PD-1 inhibitor immunotherapy. Case Rep Oncol Med. 2018 Jan 31;2018:8408015.[Abstract][Full Text]
31. Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996 Nov 21;335(21):1570-80.[Abstract]
32. Haque SK, Ariceta G, Battle G. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012 Dec;27(12):4273-87.[Abstract][Full Text]
33. Sly WS, Hewett-Emmett D, Whyte MP, et al. Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci U S A. 1983 May;80(9):2752-6.[Abstract]
34. Sly WS, Whyte MP, Sundaram V, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med. 1985 Jul 18;313(3):139-45.[Abstract]
35. Batlle D, Moorthi KM, Schluter W, et al. Distal renal tubular acidosis and the potassium enigma. Semin Nephrol. 2006 Nov;26(6):471-8.[Abstract]
36. Karet FE, Finberg KE, Nelson RD, et al: Mutations in the gene encoding the B1 subunit of H+-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet. 1999 Jan;21(1):84-90.[Abstract]
37. Smith AN, Skaug J, Choate KA, et al. Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. Nat Genet. 2000 Sep;26(1):71-5.[Abstract]
38. Zhang J, Fuster DG, Cameron MA, et al. Incomplete distal renal tubular acidosis from a heterozygous mutation of the V-ATPase B1 subunit. Am J Physiol Renal Physiol. 2014 Nov 1;307(9):F1063-71.[Abstract][Full Text]
39. Kurtz I. Renal tubular acidosis: H+/base and ammonia transport abnormalities and clinical syndromes. Adv Chronic Kidney Dis. 2018 Jul;25(4):334-50.[Abstract][Full Text]
40. Karet FE, Gainza FJ, Gyory AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6337-42.[Abstract]
41. Morris RC Jr. Renal tubular acidosis. Mechanisms, classification and implications. N Engl J Med. 1969 Dec 18;281(25):1405-13.[Abstract]
42. Igarashi T, Inatomi J, Sekine T, et al. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet. 1999 Nov;23(3):264-6.[Abstract]
43. Bernarado AA, Bernardo CM, Espiritu DJ, et al. The sodium bicarbonate cotransporter: structure, function, and regulation. Semin Nephrol. 2006 Sep;26(5):352-60.[Abstract]
44. Magen D, Berger L, Coady MJ, et al. A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med. 2010 Mar 25;362(12):1102-9.[Abstract][Full Text]
45. Morimoto T, Uchida S, Sakamoto H, et al. Mutations in CLCN5 chloride channel in Japanese patients with low molecular weight proteinuria. J Am Soc Nephrol. 1998 May;9(5):811-8.[Abstract][Full Text]
46. Lowe M. Structure and function of the Lowe syndrome protein OCRL1. Traffic. 2005 Sep;6(9):711-9.[Abstract][Full Text]
47. Choudhury R, Diao A, Zhang F, et al. Lowe syndrome protein OCRL1 interacts with clathrin and regulates protein trafficking between endosomes and the trans-Golgi network. Mol Biol Cell. 2005 Aug;16(8):3467-79.[Abstract][Full Text]
48. Klootwijk ED, Reichold M, Helip-Wooley A, et al. Mistargeting of peroxisomal EHHADH and inherited renal Fanconi's syndrome. N Engl J Med. 2014 Jan 9;370(2):129-38.[Abstract]
49. Sacré A, Jouret F, Manicourt D, et al. Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase. Nephrol Dial Transplant. 2006 Oct;21(10):2995-6.[Abstract][Full Text]
50. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004 Aug 5;351(6):585-92.[Abstract]
51. Sastrasinh S, Tannen RL. Effect of potassium on renal NH3 production. Am J Physiol. 1983 Apr;244(4):F383-91.[Abstract]
52. Andersen OS, Silveira JE, Steinmetz PR. Intrinsic characteristics of the proton pump in the luminal membrane of a tight urinary epithelium. The relation between transport rate and delta mu H. J Gen Physiol. 1985 Aug;86(2):215-34.[Abstract][Full Text]
53. Lopez-Garcia SC, Emma F, Walsh SB, et al. Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrol Dial Transplant. 2019 Jun 1;34(6):981-91.[Abstract]
54. Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med. 1981 Feb 12;304(7):373-80.[Abstract]
55. Thirakomen K, Kozlov N, Arruda JA, et al. Renal hydrogen ion secretion after release of unilateral ureteral obstruction. Am J Physiol. 1976 Oct;231(4):1233-9.[Abstract]
56. Hanley MJ, Davidson K. Isolated nephron segments from rabbit models of obstructive nephropathy. J Clin Invest. 1982 Jan;69(1):165-74.[Abstract]
57. Sabatini S, Kurtzman NA. Enzyme activity in obstructive uropathy: basis for salt wastage and the acidification defect. Kidney Int. 1990 Jan;37(1):79-84.[Abstract]
58. Sebastian A, Schambelan M, Lindenfeld S, et al. Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism. N Engl J Med. 1977 Sep 15;297(11):576-83.[Abstract]
59. Sebastian A, Schambelan M, Sutton JM. Amelioration of hyperchloremic acidosis with furosemide therapy in patients with chronic renal insufficiency and type 4 renal tubular acidosis. Am J Nephrol. 1984;4(5):287-300.[Abstract]
60. Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med. 1982 Jul 22;307(4):217-21.[Abstract]
61. Higashihara E, Nutahara K, Tago K, et al. Medullary sponge kidney and renal acidification defect. Kidney Int. 1984 Feb;25(2):453-9.[Abstract]
62. Morris RC, Yamauchi H, Palubinskas AJ, et al. Medullary sponge kidney. Am J Med. 1965 Jun;38:883-92.[Abstract]
63. Preminger GM, Sakhaee K, Skurla C, et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985 Jul;134(1):20-3.[Abstract]
64. Buckalew VM Jr, Purvis ML, Shulman MG, et al. Hereditary renal tubular acidosis. Report of a 64 member kindred with variable clinical expression including idiopathic hypercalciuria. Medicine (Baltimore). 1974 Jul;53(4):229-54.[Abstract]
65. Coe FL, Parks JH. Stone disease in heredity distal renal tubular acidosis. Ann Intern Med. 1980 Jul;93(1):60-1.[Abstract]
66. McCurdy DK, Frederic M, Elkinton JR. Renal tubular acidosis due to amphotericin B. N Engl J Med. 1968 Jan 18;278(3):124-30.[Abstract]
67. Patterson RM, Ackerman GL. Renal tubular acidosis due to amphotericin B nephrotoxicity. Arch Intern Med. 1971 Feb;127(2):241-4.[Abstract]
68. Lee DB, Drinkard JP, Rosen VJ, et al. The adult Fanconi syndrome: observations on etiology, morphology, renal function and mineral metabolism in three patients. Medicine (Baltimore). 1972 Mar;51(2):107-38.[Abstract]
69. Wegienka LC, Weller JM. Renal tubular acidosis caused by degraded tetracycline. Arch Intern Med. 1964 Aug;114:232-5.[Abstract]
70. Russo JC, Adelman RD. Gentamicin-induced Fanconi syndrome. J Pediatr. 1980 Jan;96(1):151-3.[Abstract]
71. Chisolm JJ Jr, Harrison HC, Eberlein WR, et al. Amino-aciduria, hypophosphatemia, and rickets in lead poisoning; study of a case. AMA Am J Dis Child. 1955 Feb;89(2):159-68.[Abstract]
72. Morris RC Jr. The clinical spectrum of Fanconi's syndrome. Calif Med. 1968;1108:225.
73. Lu M, Holliday LS, Zhang L, et al. Interaction between aldolase and vacuolar H+-ATPase: evidence for direct coupling of glycolysis to the ATP-hydrolyzing proton pump. J Biol Chem. 2001 Aug 10;276(32):30407-13.[Abstract][Full Text]
74. Morris RC Jr. An experimental renal acidification defect in patients with hereditary fructose intolerance. II. Its distinction from classic renal tubular acidosis; its resemblance to the renal acidification defect associated with the Fanconi syndrome of children with cystinosis. J Clin Invest. 1968 Jul;47(7):1648-63.[Abstract]
75. Sokol RJ, Twedt D, McKim JM, et al. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. Gastroenterology. 1994 Dec;107(6):1788-98.[Abstract]
76. Morgan HG, Stewart WK, Lowe KG, et al. Wilson's disease and the Fanconi syndrome. Q J Med. 1962 Jul;31:361-84.[Abstract]
77. Cuthbert JA. Wilson's disease: a new gene and an animal model for an old disease. J Invest Med. 1995 Aug;43(4):323-36.[Abstract]
78. Holton JB, Walter JH, Tyfield LA. Galactosemia. In: Scriver CR, Beaudet AL, Sly SD, et al, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York, NY: McGraw-Hill; 2001:1553-87.
79. Chen YT. Glycogen storage diseases. In: Scriver CR, Beaudet AL, Sly SD, et al, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York, NY: McGraw-Hill; 2001:1521-51.
80. Spencer AG, Franglen GT. Gross amino-aciduria following a Lysol burn. Lancet. 1952 Jan 26;1(6700):190-2.[Abstract]
81. Roth KS, Carter BE, Higgins ES. Succinylacetone effects on renal tubular phosphate metabolism: a model for experimental renal Fanconi syndrome. Proc Soc Exp Biol Med. 1991 Apr;196(4):428-31.[Abstract]
82. Goyer RA, Krall A, Kimball JP. The renal tubule in lead poisoning: II. In vitro studies of mitochondrial structure and function. Lab Invest. 1968 Jul;19(1):78-83.[Abstract]
83. Nordberg GF, Jin T, Nordberg M. Subcellular targets of cadmium nephrotoxicity: cadmium binding to renal membrane proteins in animals with or without protective metallothionein synthesis. Environ Health Perspect. 1994 Sep;102 Suppl 3:191-4.[Abstract][Full Text]
84. Adams RG, Harrison JF, Scott P. The development of cadmium-induced proteinuria, impaired renal function, and osteomalacia in alkaline battery workers. Q J Med. 1969 Oct;38(152):425-43.[Abstract]
85. Ho PT, Zimmerman K, Wexler LH, et al. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15;76(12):2557-64.[Abstract]
86. Sprangers B, Lapman S. The growing pains of ifosfamide. Clin Kidney J. 2020 Aug;13(4):500-3.[Abstract][Full Text]
87. Gahl, WA, Thoene JG, Schneider JA. Cystinosis: a disorder of lysosomal membrane transport. In: Scriver CR, Beaudet AL, Sly SD, et al, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York, NY: McGraw-Hill; 2001:5085-108.
88. Kamel DS, Ethier JH, Quaggin S, et al. Studies to determine the basis of hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol. 1992 Feb;2(8):1279-84.[Abstract]
89. O'Kelly R, Magee F, McKenna TJ. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab. 1983 Jan;56(1):108-12.[Abstract]
90. Batlle D, Gaviria M, Grupp M, et al. Distal nephron function in patients receiving chronic lithium therapy. Kidney Int. 1982 Mar;21(3):477-85.[Abstract]
91. Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int. 1986 Oct;30(4):546-54.[Abstract]
92. Roscoe JM, Goldstein MB, Halperin ML, et al: Lithium-induced impairment of urine acidification. Kidney Int. 1976 Apr;9(4):344-50.[Abstract]
93. Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intern Med. 1979 Mar;90(3):338-40.[Abstract]
94. Kleyman TR, Roberts C, Ling BN. A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med. 1995 Jan 15;122(2):103-6.[Abstract]
95. Tan SY, Shapiro R, Franco R, et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med. 1979 May;90(5):783-5.[Abstract]
96. Choi MJ, Fernandez PC, Patnaik A, et al. Trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993 Mar 11;328(10):703-6.[Abstract]
97. Seldin DW, Portwood RM, Rector FC Jr, et al. Characteristics of renal bicarbonate reabsorption in man. J Clin Invest. 1959 Oct;38:1663-71.[Abstract]
98. Maldonado JE, Velosa JA, Kyle RA, et al. Fanconi syndrome in adults: a manifestation of a latent form of myeloma. Am J Med. 1975 Mar;58(3):354-64.[Abstract]
99. Rochman J, Lichtig C, Osterweill D, et al. Adult Fanconi's syndrome with renal tubular acidosis in association with renal amyloidosis: occurrence in a patient with chronic lymphocytic leukemia. Arch Intern Med. 1980 Oct;140(10):1361-3.[Abstract]
100. Wilson DM, Goldstein NP. Bicarbonate excretion in Wilson's disease (hepatolenticular degeneration). Mayo Clin Proc. 1974 Jun;49(6):394-400.[Abstract]
101. Ahya SN, Jose Soler M, Levitsky J, et al. Acid-base and potassium disorders in liver disease. Semin Nephrol. 2006 Nov;26(6):466-70.[Abstract]
102. Caruana RJ, Barish CF, Buckalew VM Jr. Complete distal tubular acidosis in systemic lupus: clinical and laboratory findings. Am J Kidney Dis. 1985 Jul;6(1):59-63.[Abstract]
103. Mason AM, Golding PL. Renal tubular acidosis and autoimmune thyroid disease. Lancet. 1970 Nov 28;2(7683):1104-7.[Abstract]
104. Jaeger P, Portman L, Wauters JP, et al. Distal renal tubular acidosis and lymphocytic thyroiditis with spontaneously resolving hyperthyroidism. Am J Nephrol. 1985;5(2):116-20.[Abstract]
105. Batlle DC, Mozes MF, Manaligod J, et al. The pathogenesis of hyperchloremic metabolic acidosis associated with kidney transplantation. Am J Med. 1981 Apr;70(4):786-96.[Abstract]
106. Cohen EP, Bastani B, Cohen MR, et al. Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J Am Soc Nephrol. 1992 Aug;3(2):264-71.[Abstract]
107. DeFranco PE, Haragasim L, Schmitz PG, et al. Absence of vacuolar H(+)-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjogren's syndrome. J Am Soc Nephrol. 1995 Aug;6(2):295-301.[Abstract]
108. Dineshkumar T, Myvizhiselvi M, Dhanapriya J, et al. Renal manifestations of primary Sjogren's syndrome. J Integr Nephrol Androl. 2018 Jul-Sept;5(3):109-12.[Full Text]
109. Jelaković B, Dika Ž, Arlt VM, et al. Balkan endemic nephropathy and the causative role of aristolochic acid. Semin Nephrol. 2019 May;39(3):284-96.[Abstract]
110. Stiborová M, Arlt VM, Schmeiser HH. Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol. 2016 Nov;90(11):2595-615.[Abstract][Full Text]
111. Kaitwatcharachai C, Vasuvattakul S, Yenchitsomanus P, et al. Distal renal tubular acidosis and high urine carbon dioxide tension in a patient with southeast Asian ovalocytosis. Am J Kidney Dis. 1999 Jun;33(6):1147-52.[Abstract]
112. Vasuvattakul S, Yenchitsomanus PT, Vachuanichsanong P, et al. Autosomal recessive distal renal tubular acidosis associated with Southeast Asian ovalocytosis. Kidney Int. 1999 Nov;56(5):1674-82.[Abstract]
113. Tosukhowong P, Tungsanga K, Eiam-Ong S, et al. Environmental distal renal tubular acidosis in Thailand: an enigma. Am J Kidney Dis.1999 Jun;33(6):1180-6.[Abstract]
114. Vaziri ND, Ness RL, Farishter RD, et al. Nephrotoxicity of paraquat in man. Arch Intern Med. 1979 Feb;139(2):172-4.[Abstract]
115. Moss AH, Gabow PH, Kaehny WD, et al. Fanconi's syndrome and distal renal tubular acidosis after glue sniffing. Ann Intern Med. 1980 Jan;92(1):69-70.[Abstract]
116. Lambert AP, Close C. Life-threatening hypokalaemia from abuse of Nurofen plus. J Royal Soc Med. 2005 Jan;98(1):21.[Abstract][Full Text]
117. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009 May;49(5 Suppl):S185-95.[Abstract][Full Text]
118. Zhao X, Sun K, Lan Z, et al. Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity. Sci Rep. 2017 Apr 11;7:46344.[Abstract][Full Text]
119. Vittecoq D, Dumitrescu L, Beaufils H, et al. Fanconi syndrome associated with cidofovir therapy [letter]. Antimicrob Agents Chemother. 1997 Aug;41(8):1846.[Abstract][Full Text]
120. Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004 Aug 15;117(4):282-4.[Abstract]
121. Herrmann SM, Alexander MP, Romero MF, et al. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor - a report of 3 cases. Kidney Med. 2020 Sep-Oct;2(5):657-62.[Abstract][Full Text]
122. Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev. 2015 Nov 23;(11):CD010481.[Abstract][Full Text]
123. Soares SBM, de Menezes Silva LAW, de Carvalho Mrad FC, et al. Distal renal tubular acidosis: genetic causes and management. World J Pediatr. 2019 Oct;15(5):422-31.[Abstract]
124. Batlle DC, Hizon M, Cohen E, et al. The use of urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. N Engl J Med. 1988 Mar 10;318(10):594-9.[Abstract]
125. Oh MS, Carroll HJ. Value and determinants of urine anion gap. Nephron. 2002 Mar;90(3):252-5.[Abstract]
126. Laski ME, Kurtzman NA. Evaluation of acid-base disorders from the urine. In: Seldin DW and Giebisch G, eds. The regulation of acid-base balance. New York, NY: Raven Press; 1989:265-83.
127. Vallo A, Rodriguez-Soriano J. Oral phosphate-loading test for the assessment of distal urinary acidification in children. Miner Electrolyte Metab. 1984;10(6):387-90.[Abstract]
128. Halperin ML, Goldstein MB, Haig A, et al. Studies on the pathogenesis of type 1 (distal) renal tubular acidosis as revealed by the urinary PCO2 tensions. J Clin Invest. 1974 Mar;53(3):669-77.[Abstract]
129. Stinebaugh BJ, Shloeder FX, Gharafry E, et al. Mechanism by which neutral phosphate infusion elevates urine PCO2. J Lab Clin Med. 1977 May;89(5):946-58.[Abstract]
130. Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore). 1977 Jan;56(1):38-54.[Abstract]
131. Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis: core curriculum 2016. Am J Kidney Dis. 2016 Sep;68(3):488-98.[Abstract][Full Text]
132. Halperin ML, Margolis BL, Robinson LA, et al. The urine osmolal gap: a clue to estimate urine ammonium in "hybrid" types of metabolic acidosis. Clin Invest Med. 1988 Jun;11(3):198-202.[Abstract]
133. Andreucci E, Bianchi B, Carboni I, et al. Inner ear abnormalities in four patients with dRTA and SNHL: clinical and genetic heterogeneity. Pediatr Nephrol. 2009 Nov;24(11):2147-53.[Abstract]
134. Mul D, Grote FK, Goudriaan JR, et al. Should blood gas analysis be part of the diagnostic workup of short children? Auxological data and blood gas analysis in children with renal tubular acidosis. Horm Res Paediatr. 2010;74(5):351-7.[Abstract]
135. Hall PW III, Piscator M, Vasiljevic M, et al. Renal function studies on individuals with the tubular proteinuria of endemic Balkan nephropathy. Q J Med. 1972 Oct;41(164):385-93.[Abstract]
136. Oduwole AO, Giwa OS, Arogundade RA. Relationship between rickets and incomplete distal renal tubular acidosis in children. Ital J Pediatr. 2010 Aug 11;36:54.[Abstract][Full Text]
137. Wrong O, Davies W. The excretion of acid in renal disease. Q J Med. 1959 Apr;28(110):259-313.[Abstract]
138. Walsh SB, Shirley DG, Wrong OM, et al. Urinary acidification assessed by simultaneous furosemide and fludrocortisones treatment: an alternative to ammonium chloride. Kidney Int. 2007 Jun;71(12):1310-6.[Abstract]
139. Alon U, Hellerstein S. Assessment and interpretation of the tubular threshold for phosphate in infants and children. Pediatr Nephrol. 1994 Apr;8(2):250-1.[Abstract]
140. Brodehl J. Fanconi syndrome. In: Davison AM, Cameron JS, Grunfeld JP, et al, eds. Oxford textbook of clinical nephrology. 2nd ed. New York, NY: Oxford University Press; 1998:1019-37.
141. Domrongkitchaiporn S, Khositseth S, Stitchantrakul W, et al. Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. Am J Kidney Dis. 2002 Feb;39(2):383-91.[Abstract]
142. Rodriguez-Soriano J, Vallo A, Castillo G, et al. Natural history of primary distal renal tubular acidosis treated since infancy. J Pediatr. 1982 Nov;101(5):669-76.[Abstract]
143. An J, Braam B. Complete hypokalemic quadriparesis as a first presentation of Sjögren syndrome. Can J Kidney Health Dis. 2018 May 10;5:2054358118774536.[Abstract][Full Text]
144. Bruce LJ, Cope DL, Jones GK, et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest. 1997 Oct 1;100(7):1693-707.[Abstract]
145. McSherry E, Morris RC Jr. Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest. 1978 Feb;61(2):509-27.[Abstract]
146. Nash MA, Torrado AD, Greifer I, et al. Renal tubular acidosis in infants and children. Clinical course, response to treatment, and prognosis. J Pediatr. 1972 May;80(5):738-48.[Abstract]
147. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8.[Abstract][Full Text]
148. Stavros F, Yang A, Leon A, et al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014;9(12):e114686.[Abstract][Full Text]
149. Roger SD, Lavin PT, Lerma EV, et al. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant. 2021 Jan 1;36(1):137-50.[Abstract][Full Text]
150. Clericetti CM, Milani GP, Lava SAG, et al. Hyperammonemia associated with distal renal tubular acidosis or urinary tract infection: a systematic review. Pediatr Nephrol. 2018 Mar;33(3):485-91.[Abstract]
Key Articles
Referenced Articles
Sign in to access our clinical decision support tools